Percutaneous Pulmonary Valve Implantation
| Autor: | Mario Carminati, Luca Giugno, Alessia Faccini |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Percutaneous Percutaneous pulmonary valve implantation business.industry medicine.medical_treatment Review Article 030204 cardiovascular system & hematology Prosthesis Surgery 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Maximum diameter Pulmonary valve Internal Medicine Medicine Ventricular outflow tract Initial treatment Transcatheter procedure 030212 general & internal medicine Cardiology and Cardiovascular Medicine business Edwards sapien Congenital heart disease |
| Zdroj: | Korean Circulation Journal |
| ISSN: | 1738-5520 |
| Popis: | Percutaneous pulmonary valve implantation (PPVI) is recognized as a feasible and low risk alternative to surgery to treat dysfunctional right ventricular outflow tract (RVOT) in usually pluri-operated patients. Evolving technology allowed to develop different kind of prosthesis and to go from an initial treatment exclusively of stenotic conduit to an actual approach extended also to wide native RVOT. The Melody transcatheter pulmonary valve (TPV) and the Edwards Sapien valve are nowadays the most commonly implanted prostheses. However, other devices have been developed to treat large RVOT (i.e., the Venus p-valve, the Medtronic Harmony TPV, the Alterra Adaptive Prestent, and the Pulsta valve). Indications for PPVI are the same as for surgical interventions on pulmonary valve, with limits related to the maximum diameter of the available percutaneous prosthesis. Therefore, an accurate preoperative evaluation is of paramount importance to select patients who could benefit from this procedure. The overall periprocedural mortality incidence is around 1.4%, while freedom from RVOT reintervention ranges from 100% at 4 months to 70% at 70 months, according to the different published studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|